GAS6/TAM pathway signaling in hemostasis and thrombosis

Luke A. Law, Douglas K. Graham, Jorge Di Paola, Brian R. Branchford

Research output: Contribution to journalShort surveypeer-review

38 Scopus citations


The GAS6/TYRO3-AXL-MERTK (TAM) signaling pathway is essential for full and sustained platelet activation, as well as thrombus stabilization. Inhibition of this pathway decreases platelet aggregation, shape change, clot retraction, aggregate formation under flow conditions, and surface expression of activation markers. Transgenic mice deficient in GAS6, or any of the TAM family of receptors that engage this ligand, exhibit in vivo protection against arterial and venous thrombosis but do not demonstrate either spontaneous or prolonged bleeding compared to their wild-type counterparts. Comparable results are observed in wild-type mice treated with pharmacological inhibitors of the GAS6-TAM pathway. Thus, GAS6/TAM inhibition offers an attractive novel therapeutic option that may allow for a moderate reduction in platelet activation and decreased thrombosis while still permitting the primary hemostatic function of platelet plug formation.

Original languageEnglish
Article number137
JournalFrontiers in Medicine
Issue numberMAY
StatePublished - May 1 2018


  • AXL
  • GAS6
  • Platelet activation
  • Signaling pathways
  • TYRO3


Dive into the research topics of 'GAS6/TAM pathway signaling in hemostasis and thrombosis'. Together they form a unique fingerprint.

Cite this